# US 12,600,773 B2 · Treatment of diuretic resistant heart failure patients having at least one copy of the TMPRSS6 rs855791 allele

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,600,773 B2
- Document ID: US12600773B2
- Status: Granted
- Kind: B2
- Application number: 17/519,082
- Filed: 2021-11-04
- Published: 2022-06-23
- Granted: 2026-04-14
- Earliest claimed: 2017-02-01
- Assignees: Novo Nordisk A/S; Yale University
- Applicants: Yale University; Novo Nordisk A/S
- Inventors: Jeffrey Testani; Veena Rao; Rahul Kakkar; Madhav N. Devalaraja; Chih-Hung Lo
- Web page: https://patentgrep.com/patent/US12600773B2

## CPC

- A61P 7/10: Antioedematous agents; Diuretics
- C07K 16/248: {IL-6}
- A61P 13/12: of the kidneys
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated urine levels of IL-6, plasma levels of IL-6, or both urine and plasma levels of IL-6.

## Claims

### Claim 1

A method of treating a patient with diuretic resistant heart failure having at least one copy of the TMPRSS6 rs855791 allele who requires diuresis but is resistant to diuretics, comprising:
administering, in combination with a diuretic, a therapeutically effective amount of an IL-6 antagonist to the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has acute heart failure.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient has chronic heart failure.

### Claim 4 (depends on 1)

The methods of claim 1, wherein the patient has cardiorenal syndrome.

### Claim 5 (depends on 4)

The method of claim 4, wherein the patient has cardiorenal syndrome type 4.

### Claim 6 (depends on 1)

The methods of claim 1, wherein the patient has kidney disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the IL-6 antagonist is an anti-IL-6 antibody, or antigen-binding fragment or derivative thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the IL-6 antagonist is an anti-IL-6R antibody, or antigen-binding fragment or derivative thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the IL-6 antagonist is a JAK inhibitor.

### Claim 10 (depends on 1)

The method of claim 1, wherein the IL-6 antagonist is a STAT3 inhibitor.